Invesco Ltd. Raises Stock Holdings in Prestige Consumer Healthcare Inc. $PBH

Key Points

• Invesco Ltd. increased its stake in Prestige Consumer Healthcare Inc. by 24.7%, acquiring an additional 261,537 shares, bringing its total ownership to approximately 2.67% of the company valued at $113.6 million.
• Prestige Consumer Healthcare's recent earnings report showed an EPS of $0.95, missing the consensus estimate of $1.01, with revenue of $249.53 million, which was down 6.6% year over year.
• Analysts have mixed views on Prestige Consumer Healthcare, with a current average rating of "Hold" and a price target of $93.33, following several recent upgrades and downgrades.

Invesco Ltd. grew its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 24.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,321,800 shares of the company's stock after acquiring an additional 261,537 shares during the quarter. Invesco Ltd. owned 2.67% of Prestige Consumer Healthcare worth $113,635,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the stock. Kayne Anderson Rudnick Investment Management LLC bought a new stake in Prestige Consumer Healthcare in the fourth quarter worth $84,932,000. Congress Asset Management Co. boosted its holdings in Prestige Consumer Healthcare by 9.1% in the first quarter. Congress Asset Management Co. now owns 991,580 shares of the company's stock worth $85,246,000 after acquiring an additional 82,838 shares in the last quarter. Westwood Holdings Group Inc. boosted its holdings in Prestige Consumer Healthcare by 7.1% in the first quarter. Westwood Holdings Group Inc. now owns 861,282 shares of the company's stock worth $74,044,000 after acquiring an additional 56,802 shares in the last quarter. Northern Trust Corp boosted its holdings in Prestige Consumer Healthcare by 10.9% in the fourth quarter. Northern Trust Corp now owns 813,076 shares of the company's stock worth $63,493,000 after acquiring an additional 80,055 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 1.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 642,390 shares of the company's stock valued at $55,226,000 after purchasing an additional 6,370 shares in the last quarter. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock traded up $0.0160 during mid-day trading on Tuesday, reaching $64.8860. 101,928 shares of the stock traded hands, compared to its average volume of 386,604. The stock has a market capitalization of $3.19 billion, a PE ratio of 15.24, a price-to-earnings-growth ratio of 2.05 and a beta of 0.43. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. Prestige Consumer Healthcare Inc. has a 12-month low of $62.95 and a 12-month high of $90.04. The business's 50-day moving average is $76.85 and its 200-day moving average is $81.54.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). The firm had revenue of $249.53 million for the quarter, compared to analysts' expectations of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The firm's revenue was down 6.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. As a group, sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on PBH. Canaccord Genuity Group lowered their price target on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Wall Street Zen downgraded Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.